Diabetes: What is the scope of the problem?

Transcription

1 Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes Research University of Minnesota

2 Diabetes Mellitus A disorder of glucose metabolism resulting in hyperglycemia as a result of insulin deficiency or abnormal insulin secretion and action.

3 Impact of Type 1 and Type 2 Diabetes Individuals diagnosed by 1.3 million each year 6th leading cause of death Diabetes Increasingly affects all age groups Especially prevalent in African and Hispanic Americans Shortens average life expectancy by up to 15 years Adapted from Accessed 2/10/04. Diabetes Research Working Group. NIH Pub # ;1999:1 129.

4 Diabetes Trends* Among Adults in the U.S., (Includes Gestational Diabetes) BRFSS, 1990,1995 and No Data <4% 4-6% 6-8% 8-10% >10% Source: Mokdad et al., Diabetes Care 2000;23: ; J Am Med Assoc 2001;286:10.

5 2002 Diabetes prevalence in US by age, gender, race 30 Prevalence per 100 people >75 0 White male White female Black male Black female Hispanic male Hispanic female CDC

6 Gestational diabetes 3-5% Other 1-2% Type 1 diabetes 5-10% Type 2 diabetes 90-95%

7 Type 1 Diabetes Mellitus Insulin Dependent Diabetes Mellitus (IDDM), Type I Diabetes, Ketosis-prone diabetes, Juvenile onset diabetes mellitus Caused by an absolute deficiency of insulin Occurs because of autoimmune destruction of pancreatic beta cells Arises in genetically susceptible individuals exposed to a triggering factor

8

9 Type 1 diabetes Peak time of clinical onset is at puberty but can present at any age Patients are usually lean Concordance rate for identical twins is ~50% Insulin therapy is required for survival

10 Type 2 Diabetes Mellitus Non-insulin dependent diabetes mellitus (NIDDM), Adult onset diabetes mellitus Occurs because of a defect in both insulin secretion and insulin action Primary defect probably varies by population but failure to compensate for primary defect ultimately leads to hyperglycemia

11 Prentki, M. et al. J. Clin. Invest. 2006;116: Copyright 2006 American Society for Clinical Investigation

12 Type 2 diabetes Usually presents in adulthood Patients are usually obese at presentation Concordance rate for identical wins is >90% Long prodrome (period of impaired glucose intolerance) often undetected Long-term complications may be present at time of diagnosis

13 Diabetic Complications Microvascular Complications Diabetic Retinopathy Macrovascular Complications Stroke Diabetic Nephropathy Heart Disease Diabetic Neuropathy Peripheral Vascular Disease Harris MI. Clin Invest Med 1995;18: Nelson RG et al. Adv Nephrol Necker Hosp 1995;24: World Health Organization, 2002;Fact Sheet N 138

14 Effect of Glycemic Control on Incidence of Diabetic Complications in Patients With Type 1 Diabetes Estimated Lifetime Cumulative Incidences Conventional Therapy Intensive Therapy Difference Between Therapies 100 Microalbuminuria Proliferative Retinopathy Blindness Albuminuria Nephropathy End-stage renal disease Neuropathy Neuropathy Data derived from Rathmann W. Drug Benefit Trends. 1998;24 33.

15 Food Exercise Glucose Control Drugs

16

17 Hirsch I. N Engl J Med 2005;352:

18 Typical course for type 2 diabetes Usual sequence Year of interventions Diet Oral Agents Combination Therapy with Oral agents Insulin Usual Clinical Course Onset of Diabetes Diagnosis Development of complications Death

19

20

21 Role of Incretins in Glucose Homeostasis Ingestion of food GI tract Release of gut hormones Incretins 1,2 Active GLP-1 & GIP DPP-4 enzyme Pancreas 2,3 Glucose-dependent Insulin from beta cells (GLP-1 and GIP) Beta cells Alpha cells Glucose dependent Glucagon from alpha cells (GLP-1) Glucose uptake by muscles 2,4 Glucose production by liver Blood glucose Inactive GLP-1 Inactive GIP DPP-4 = dipeptidyl-peptidase 4 1. Kieffer TJ, Habener JF. Endocr Rev. 1999;20: Ahrén B. Curr Diab Rep. 2003;2: Drucker DJ. Diabetes Care. 2003;26: Holst JJ. Diabetes Metab Res Rev. 2002;18:

22 Incretin therapies GLP-1 analog (Exenatide) Administered twice daily by subcutaneous injection Lowers A1c % Side effects are weight loss, nausea, hypoglycemia DPP-1 inhibitors (vitagliptin, sidagliptin) Orally administered once a day Lowers A1c by ~0.5% Not associated with weight loss or nausea

23 Economic Consequences of Diabetes in the United States Direct Costs: $92 Billion Indirect Costs: $40 Billion Annual Total: $132 Billion* Indirect costs due to disability and early mortality: $40 billion Excess prevalence of general medical conditions: $44 billion Diabetes/ diabetes supplies: $23 billion Excess prevalence of chronic complications: $25 billion *Approximate 2002 US Dollars Hogan P, et al. Diabetes Care. 2003;26:

24 Total Per Capita Health Care Expenditure ,000 13,243 12,000 $ 10,000 8,000 6,000 4,000 2,560 2,000 0 Diabetes Without Diabetes ADA. Diabetes Care. 2003;26: